
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc is a clinical-stage biotechnology company with promising potential driven by its allogeneic gamma delta T cell therapies, particularly the product candidate ADI-001, which exhibits significant efficacy in treating autoimmune diseases like lupus nephritis and systemic lupus erythematosus. The company is poised for expansion into oncology with the anticipated Ph1 study of ADI-212 targeting metastatic castration-resistant prostate cancer set to begin in 2026, potentially introducing new avenues for growth and value creation. Additionally, the planned collaboration with third-party manufacturers for commercial-scale production mitigates manufacturing risks, further supporting a positive outlook on the company’s operational stability and growth trajectory.
Bears say
Adicet Bio Inc faces a negative outlook primarily due to an anticipated net loss of $1.13 per share for 2025, coupled with the possibility that its lead product candidate, ADI-001, may underperform in efficacy compared to expectations, particularly in patients who have previously failed anti-CD20 therapies. There are significant concerns regarding the company's pipeline, with increased risks related to negative clinical data, prolonged developmental timelines, potential setbacks in later-stage studies, and challenges in obtaining regulatory approvals, which may lead to reduced commercial success and long-term dilution of shareholder value. Additionally, the company's probability of success for key indications has been downgraded, now standing at 15%, alongside a raised discount rate reflecting a more conservative financial stance.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares